Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver

被引:23
作者
Ferrao, PT
Gonda, TJ
Ashman, LK
机构
[1] Univ Newcastle, Fac Hlth, Sch Biomed Sci, Callaghan, NSW 2308, Australia
[2] Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia
关键词
c-Kit; D816V mutation; transformation; differentiation; megakaryocyte; mast cell;
D O I
10.1016/S0145-2126(02)00272-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mutations of Kit at position D816 have been implicated in mastocytosis, acute myeloid leukaemia and germ cell tumours. Expression of this mutant Kit in cell lines results in factor-independent growth, differentiation and increased survival in vitro and tumourigenicity in vivo. Mutant D816VKit and wild-type Kit were expressed in murine primary haemopoietic cells and grown in stem cell factor (SCF) or the absence of factors. Expression of D816VKit did not lead to transformation as assessed by a colony assay, but resulted in enhanced differentiation of cells when compared to control cells. D816VKit induced an increase in the number of cells differentiating along the megakaryocyte lineage in the absence of factors. SCF had an added effect with an increase in differentiation of mast cells. Expression of wild-type Kit in the presence of SCF also failed to cause transformation and induced differentiation of mast cells and megakaryocytes. We conclude that constitutive expression of D816VKit in primary haemopoietic cells is not a sufficient transforming stimulus but leads to the survival and maturation of cells whose phenotype is influenced by the presence of SCF. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:547 / 555
页数:9
相关论文
共 64 条
[11]   Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: effect of receptor density and ligand-requirement [J].
Caruana, G ;
Cambareri, AC ;
Gonda, TJ ;
Ashman, LK .
ONCOGENE, 1998, 16 (02) :179-190
[12]   Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant [J].
Chian, RJ ;
Young, S ;
Danilkovitch-Miagkova, A ;
Rönnstrand, L ;
Leonard, E ;
Ferrao, P ;
Ashman, L ;
Linnekin, D .
BLOOD, 2001, 98 (05) :1365-1373
[13]  
Cole SR, 1996, LEUKEMIA, V10, P288
[14]   Mastocytosis cells bearing a c-kit activating point mutation are characterized by hypersensitivity to stem cell factor and increased apoptosis [J].
Dror, Y ;
Leaker, M ;
Caruana, G ;
Bernstein, A ;
Freedman, MH .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 108 (04) :729-736
[15]  
Ferrao P, 1997, BLOOD, V90, P4539
[16]  
FERRAO P, 1995, ONCOGENE, V11, P1631
[17]   Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis [J].
Fritsche-Polanz, R ;
Jordan, JH ;
Feix, A ;
Sperr, WR ;
Sunder-Plassmann, G ;
Valent, P ;
Födinger, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (02) :357-364
[18]  
Frost MJ, 2002, MOL CANCER THER, V1, P1115
[19]   IDENTIFICATION OF MUTATIONS IN THE CODING SEQUENCE OF THE PROTOONCOGENE C-KIT IN A HUMAN MAST-CELL LEUKEMIA-CELL LINE CAUSING LIGAND-INDEPENDENT ACTIVATION OF C-KIT PRODUCT [J].
FURITSU, T ;
TSUJIMURA, T ;
TONO, T ;
IKEDA, H ;
KITAYAMA, H ;
KOSHIMIZU, U ;
SUGAHARA, H ;
BUTTERFIELD, JH ;
ASHMAN, LK ;
KANAYAMA, Y ;
MATSUZAWA, Y ;
KITAMURA, Y ;
KANAKURA, Y .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (04) :1736-1744
[20]  
GALLI SJ, 1994, ADV IMMUNOL, V55, P1